171 related articles for article (PubMed ID: 12943000)
1. Neurodevelopment and mood stabilizers.
Harwood AJ
Curr Mol Med; 2003 Aug; 3(5):472-82. PubMed ID: 12943000
[TBL] [Abstract][Full Text] [Related]
2. Search for a common mechanism of mood stabilizers.
Harwood AJ; Agam G
Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons.
Di Daniel E; Mudge AW; Maycox PR
Bipolar Disord; 2005 Feb; 7(1):33-41. PubMed ID: 15654930
[TBL] [Abstract][Full Text] [Related]
4. The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters.
Di Daniel E; Cheng L; Maycox PR; Mudge AW
Mol Cell Neurosci; 2006; 32(1-2):27-36. PubMed ID: 16531065
[TBL] [Abstract][Full Text] [Related]
5. Inositol synthesis regulates the activation of GSK-3α in neuronal cells.
Ye C; Greenberg ML
J Neurochem; 2015 Apr; 133(2):273-83. PubMed ID: 25345501
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
7. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.
Bachmann RF; Schloesser RJ; Gould TD; Manji HK
Mol Neurobiol; 2005 Oct; 32(2):173-202. PubMed ID: 16215281
[TBL] [Abstract][Full Text] [Related]
8. A molecular cell biology of lithium.
Williams R; Ryves WJ; Dalton EC; Eickholt B; Shaltiel G; Agam G; Harwood AJ
Biochem Soc Trans; 2004 Nov; 32(Pt 5):799-802. PubMed ID: 15494019
[TBL] [Abstract][Full Text] [Related]
9. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.
Eickholt BJ; Towers GJ; Ryves WJ; Eikel D; Adley K; Ylinen LM; Chadborn NH; Harwood AJ; Nau H; Williams RS
Mol Pharmacol; 2005 May; 67(5):1426-33. PubMed ID: 15687223
[TBL] [Abstract][Full Text] [Related]
10. A common mechanism of action for three mood-stabilizing drugs.
Williams RS; Cheng L; Mudge AW; Harwood AJ
Nature; 2002 May; 417(6886):292-5. PubMed ID: 12015604
[TBL] [Abstract][Full Text] [Related]
11. PtdIns(3,4,5)P(3) and inositol depletion as a cellular target of mood stabilizers.
Teo R; King J; Dalton E; Ryves J; Williams RS; Harwood AJ
Biochem Soc Trans; 2009 Oct; 37(Pt 5):1110-4. PubMed ID: 19754462
[TBL] [Abstract][Full Text] [Related]
12. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior.
Shimshoni JA; Dalton EC; Jenkins A; Eyal S; Ewan K; Williams RS; Pessah N; Yagen B; Harwood AJ; Bialer M
Mol Pharmacol; 2007 Mar; 71(3):884-92. PubMed ID: 17167030
[TBL] [Abstract][Full Text] [Related]
13. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons.
Yasuda S; Liang MH; Marinova Z; Yahyavi A; Chuang DM
Mol Psychiatry; 2009 Jan; 14(1):51-9. PubMed ID: 17925795
[TBL] [Abstract][Full Text] [Related]
14. Valproate recovers the inhibitory effect of dexamethasone on the proliferation of the adult dentate gyrus-derived neural precursor cells via GSK-3β and β-catenin pathway.
Boku S; Nakagawa S; Masuda T; Nishikawa H; Kato A; Takamura N; Omiya Y; Kitaichi Y; Inoue T; Kusumi I
Eur J Pharmacol; 2014 Jan; 723():425-30. PubMed ID: 24211784
[TBL] [Abstract][Full Text] [Related]
15. Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: Potential involvement of epigenetics.
Pisanu C; Papadima EM; Del Zompo M; Squassina A
Neurosci Lett; 2018 Mar; 669():24-31. PubMed ID: 27343410
[TBL] [Abstract][Full Text] [Related]
16. How can the mood stabilizer VPA limit both mania and depression?
Cheng L; Lumb M; Polgár L; Mudge AW
Mol Cell Neurosci; 2005 Jun; 29(2):155-61. PubMed ID: 15911340
[TBL] [Abstract][Full Text] [Related]
17. Specificity of mood stabilizer action on neuronal growth cones.
Shaltiel G; Dalton EC; Belmaker RH; Harwood AJ; Agam G
Bipolar Disord; 2007 May; 9(3):281-9. PubMed ID: 17430303
[TBL] [Abstract][Full Text] [Related]
18. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
Gould TD; Picchini AM; Einat H; Manji HK
Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
[TBL] [Abstract][Full Text] [Related]
19. Mood stabilizers: protecting the mood...protecting the brain.
Brunello N
J Affect Disord; 2004 Apr; 79 Suppl 1():S15-20. PubMed ID: 15121343
[TBL] [Abstract][Full Text] [Related]
20. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid.
Jonathan Ryves W; Dalton EC; Harwood AJ; Williams RS
Bipolar Disord; 2005 Jun; 7(3):260-5. PubMed ID: 15898963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
